The generic, biosimilar and value-added medicines industry appoints a new leadership team to guide the next phase of growth. Medicines for Ireland (MFI), the representative body for the suppliers of
Reforms set to generate up to €1.4 billion in value for reinvestment in the Irish healthcare system Medicines for Ireland (MFI), the representative body for
New agreement set to unlock earlier access to generic, biosimilar and value-added medicines tostrengthen supply chains, secure access for Irish patients, and deliver value for
Generic, biosimilar and value-added medicines industry leadership reinforced as it prepares for the next framework agreement on pricing and supply of medicines and responds to
Patient access to medicines at risk due to the disproportionate impact of the UWWTD Extended Producer Responsibility (EPR) scheme on generic medicine suppliers Medicines for
Generic, biosimilar and value added medicines industry call for transition to digital-first communications to improve environmental impact and end wasteful duplication of resources Medicines for
Membership expansion bolsters expertise and voice of Ireland’s generic, biosimilar and value-added medicines industry ahead of pivotal negotiations with the State on pricing and supply
Ahead of polling day, Medicines for Ireland (MFI) warmly welcomes the inclusion of several of its key priorities in the manifestos and policy papers of
Suppliers of generic, biosimilar, and value-added medicines call on political parties to ensure fair competition through patent reform, which could potentially saving the State millions.
Medicines for Ireland, alongside our colleagues in Medicines for Europe, are seriously concerned about the impact of the Urban Wastewater Treatment Directive (UWWTD). The direct
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
